Analysis of the ribosome biogenesis factors' expression in the VICTORIA clinical trial identifies a set of preliminarily RiBi‐based markers to monitor drug activity but also to predict the response to Anastrozole and mTOR inhibitor (Vistusertib) combination therapy in advanced endometrial cancer. The gene discussed is MTOR; the disease is endometrial cancer.